Table 1.
Summary of indications and efficacy of SLT
| Paper | Design | Diagnosis | Number of eyes (n) | Postoperative follow-up | Definition of success | Success rate | Average IOP reduction or medication reduction | Additional outcomes |
|---|---|---|---|---|---|---|---|---|
| Schlote et al. [13] | Retrospective chart review | Early stage of OAG (vCDR < 0.8 and GSS 0–1) | n = 27 | 12 months |
Eyes with elevated IOP prior to SLT: reduction in IOP < 21 mmHg and >20% of the initial IOP Or Eyes with discomfort to anti-glaucoma medication but controlled IOP: reduction in the number of medications ≥1 and an IOP < 21 mmHg |
63% | N/A | Re-treatment in 7.4% of eyes |
| Advanced stage of OAG (vCDR ≥ 0.9, GSS 2 ≥ 3, or vCDR 0.6–0.8 and GSS2 ≥ 2) | n = 44 |
Definition 1: Reduction in IOP < 21 mmHg and >20% of the baseline IOP Definition 2: IOP reduction <18 mmHg and no additional glaucoma medication at all time points after SLT Definition 3: IOP reduction <18 mmHg and >30% of the baseline IOP |
Definition 1: 59.1% Definition 2: 65.9% Definition 3: 50% |
N/A | Additional glaucoma surgery in 18.2% of eyes | |||
| Kerr et al. [14] | Retrospective cohort study | OAG or OHT | n = 20 | At least 6 weeks | Significant reduction in baseline IOP, peak IOP, and % rise in IOP from baseline induced by the water drinking test | N/A | Reduction in mean baseline IOP from 16.9 ± 2.4 to 14.2 ± 2.3 mmHg (P < 0.001) | Peak IOP decreased from 21.9 ± 3.7 to 16.9 ± 3.1 mmHg (P < 0.001) and rise in IOP from baseline reduced from 5.0 ± 2.5 to 2.6 ± 1.8 mmHg (P < 0.002) |
| Ali Aljasim et al. [15] | Retrospective case–control study | PAC/PACG, POAG | n = 96 (SLT), n = 99 (PGA) |
PAC/PACG: 6–20 months POAG: 6–17 months |
IOP reduction ≥20% without further medical or surgical intervention or a reduction in the number of glaucoma medications by ≥1 while maintaining the target IOP | PAC or PACG: 84.7%, POAG: 79.6% (P = 0.47) |
IOP reduction in patients with uncontrolled IOP: 38% (PAC/PACG) vs. 32.7% (POAG), P = 0.08 Number of medications reduction in patients with controlled IOP: 1.6 (PAC/PACG) vs. 1.5 (POAG), P = 0.4 |
N/A |
| Narayanaswamy et al. [16] | Randomized clinical trial | PAC/PACG | n = 20, (PXFG), n = 28 (POAG) | 6 months |
Complete success: IOP <21 mmHg and without any additional IOP-lowering medications Qualified success: IOP <21 mmHg who required IOP lowering medication |
Complete success: 60% (SLT) vs. 84% (PGA), P = 0.008 Qualified success: 18% (SLT) vs. 6% (PGA), P = 0.06 |
IOP reduction: 16.9% (SLT) vs. 18.5% (PGA), P = 0.52 |
No patient required glaucoma surgery Additional medication: 22% (SLT) vs. 8% (PGA), P = 0.05 |
| Miraftabi et al. [17] | Prospective non-randomized comparative study | PXFG, POAG | n = 94 (PXFG), n = 250 (non-PXFG) | 12 months | IOP reduction ≥20% from baseline without additional IOP-lowering medications |
At 6 months, 75% (POAG) vs. 94.1% (PXFG), P = 0.08 At 12 months, 29.1% (POAG), 25% (PXFG), P = 0.9 |
Significant IOP reduction up to 6 months post-operation | N/A |
| Lindegger et al. [18] | Retrospective chart review | PXFG | n = 41 | 60 months | N/A | N/A |
Significantly greater IOP reduction in PXFG than non-PXFG eyes at 1 year follow-up, P = 0.01 PXFG: significant IOP reduction up to 21 months, 12.4%, P = 0.01 Non-PXFG: significant IOP reduction up to 30 months, 9.6%, P = 0.01 |
N/A |
| Lee et al. [19] | Prospective cohort study | NTG | n = 34 | 12 months |
Absolute success: IOP reduction ≥20% after SLT compared to baseline without any additional anti-glaucoma medication Qualified success: IOP reduction ≥20% compared to baseline, with additional anti-glaucoma medication |
Absolute success: 22%, qualified success: 73.2% | At 12 months, IOP reduction: 14.7%, medication reduction: 26.7% | N/A |
| Lee et al. [20] | Prospective cohort study | NTG | n = 15 | 24 months | Absolute success: 11.1% | At 24 months, IOP reduction: 11.5%, medication reduction: 41.1% | N/A | |
| Maleki et al. [21] | Retrospective case series | Steroid-induced glaucoma | n = 42 | 12 months | IOP < 22 mmHg and/or >20% IOP reduction | 46.7% | At 12 months, IOP reduction: 50.4% | N/A |
| Zhang et al. [22] | Retrospective chart review | Silicone oil-induced glaucoma | n = 19 | 12 months | IOP reduction of ≥20%, without additional medications, repeat laser trabeculoplasty, or glaucoma surgery | 59.5% | At last visit, IOP reduction: 20.3%, medication reduction: 2.17 ± 1.21 to 1.25 ± 0.89 (P < 0.05) | N/A |
| Sluch et al. [23] | Retrospective chart review | Post-canaloplasty | n = 18 | N/A | IOP reduction >20% at 2–4 weeks or a decrease in the number of medications 3 months after SLT | 5 of 19 eyes (26.3%) | N/A | N/A |
| Zhang et al. [24] | Retrospective study | Post-trabeculectomy advanced POAG | 9 months | IOP reduction >20% from baseline IOP at 6 and 9 months after the laser treatment date | 100% 1 day after SLT; 77.7% at the last follow-up | IOP reduction of 16.7% in patients with pre-SLT IOP > 18 mmHg | IOP fluctuation reduced from 4.1 ± 1.4 to 2.6 ± 1.1 mmHg, P < 0.05 |
GSS glaucoma staging system, IOP intraocular pressure, NTG normal-tension glaucoma, OAG open-angle glaucoma, OHT ocular hypertension, PAC primary angle closure, PACG primary angle-closure glaucoma, PGA prostaglandin POAG primary open-angle glaucoma, PXFG pseudoexfoliation glaucoma, SLT selective laser trabeculoplasty, vCDR vertical cup-to-disc ratio